Bionomics

Bionomics is a pharmaceutical company dedicated to developing better treatments for central nervous system disorders such as anxiety, depression, and Alzheimer's disease. The company has small molecule product development programs in areas like cancer, anxiety, epilepsy, and multiple sclerosis. It is developing its lead cancer compound, BNC105, for the treatment of solid tumors including breast cancer, lung cancer, colon cancer, and prostate cancer. BNC105 belongs to a class of compounds known as vascular disrupting agents (VDAs), which shut down the blood supply within tumors, starving them and halting their continued growth.